This is the authors' abstract. We don't add key points for this paper.
Background Dalbavancin offers an alternative to prolonged inpatient antimicrobial treatment when oral therapy or conventional outpatient parenteral antimicrobial therapy (OPAT) is unsuitable. We describe its use in a selected cohort with complex, predominantly implant-associated osteoarticular infections. Methods We retrospectively included all consecutive patients treated with dalbavancin for osteoarticular infections at a Danish tertiary hospital between October 2023 and November 2024. Data was collected through structured record review. The primary outcome was treatment failure within 12 months. Secondary outcomes included new infections, adverse events, treatment completion and estimated inpatient bed-days avoided. Results Twenty patients (median age 62 years, 60% male) were included, 15 (75%) with implant-associated infections. Dalbavancin was mainly selected when linezolid or vancomycin-based OPAT was unsuitable. Eighteen (90%) completed the prescribed course; one index-infection relapse and two microbiologically distinct new infections were recorded. Four patients died from reportedly unrelated causes. No serious adverse events were reported. The estimated median number of inpatient bed-days avoided was 42 (IQR 28–72), based on a hypothetical inpatient alternative. Conclusion In this small case series, dalbavancin was well tolerated and treatment failure was uncommon among patients with complex osteoarticular infections for whom conventional oral or intravenous treatment was not feasible.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Johansen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: